PCOS Was the Wrong Name for 91 Years. Meet PMOS — And What the Science Finally Gets Right

On the morning of May 12, 2026, a paper landed in The Lancet that made 91 years of confusion suddenly make sense. For nearly a century, a condition affecting 1 in 10 women worldwide had been named after the wrong thing. Doctors looked at ovaries enlarged and full of small follicles and called them polycystic. The name stuck. It shaped how the condition was taught, diagnosed, and treated across generations of medical training. The real problem — hidden in insulin pathways, androgen feedback loops, and the complex hormonal circuits connecting them — was present in nearly every blood test. But the name kept pointing clinicians toward an organ that was, in most cases, simply responding to a storm it didn't start.

The Cysts That Were Never Cysts

In 1935, two American gynaecologists named Irving Stein and Michael Leventhal published a paper titled 'Amenorrhea Associated with Polycystic Ovaries.' They had observed seven women with absent periods, excess body hair, and obesity. On examination, their ovaries were enlarged and visually striking — dotted with small round structures that, under the technology of the 1930s, looked like cysts. The name polycystic ovary syndrome followed. It was logical given what they could see. It was also wrong about what those structures actually were.

What Stein and Leventhal called cysts were not pathological formations. They were ovarian follicles — tiny sacs that normally develop around an egg before ovulation — that had simply stopped growing at an immature stage. They were not dangerous structures that could burst. They did not require surgical treatment. They were not unique to the condition. They were the symptom of ovulation that never happened, caused by a hormonal environment that made it impossible for follicles to reach maturity. The ovary was showing a downstream effect. The name immortalized the downstream effect and ignored everything upstream.

What PMOS Actually Stands For — And Why Every Letter Finally Matters

The new name — Polyendocrine Metabolic Ovarian Syndrome — was not chosen because it sounds better. Every word in it was selected to accurately describe what the condition actually involves. Breaking it apart reveals something important: this is a condition that affects multiple hormonal systems, carries significant metabolic risk, and involves the ovaries as one of several affected organs — not the origin of the problem.

The Vicious Cycle Nobody Drew on the Whiteboard

Here is the mechanism that the old name obscured for decades. In PMOS, insulin resistance means the body produces more insulin than usual to achieve the same glucose-lowering effect. That excess insulin travels to the ovaries. Ovarian theca cells — the cells that produce androgens (including testosterone) — have insulin receptors. High insulin activates these cells directly, causing them to produce more testosterone. Excess testosterone suppresses a liver protein called sex hormone-binding globulin (SHBG), which normally keeps testosterone inactive in the blood. Less SHBG means more free testosterone circulating. More free testosterone disrupts ovulation, causes acne, drives hair growth in unwanted places, and thins the hair on the scalp. And higher testosterone levels make insulin resistance worse, which produces more insulin, which makes the ovaries produce more testosterone. The loop closes on itself.

Why 70 Percent of People with PMOS Still Don't Know They Have It

The name PCOS sent a clear signal to both patients and clinicians: this is a gynaecological problem. If a woman had irregular periods, she saw a gynaecologist. If she had acne, she saw a dermatologist. If she had weight that wouldn't move despite effort, she was often told to try harder. If she had depression or anxiety — which occur at roughly twice the rate in PMOS — she saw a mental health professional. Each specialist treated their piece of the picture. Nobody was looking at the full system. The name made sure of that.

The Lancet consensus paper noted that the fragmented care produced by the wrong name was not a failure of individual clinicians — it was a structural failure built into the diagnosis itself. A condition named after ovarian cysts will always be routed primarily through reproductive medicine. A condition named for its actual mechanism — polyendocrine, metabolic, ovarian — creates a different clinical pathway. The rename is, in this sense, a clinical infrastructure change disguised as a linguistic one.

The Skin Signals That Were Hormonal All Along

One of the most practically significant aspects of PMOS is what it does to skin — and how systematically those skin signals were misread. The insulin-androgen vicious cycle described above has a direct dermatological expression. Elevated free testosterone increases sebum (oil) production in the skin's sebaceous glands, promotes follicular hyperkeratinisation (the clogging of pores with excess skin cells), and drives inflammatory acne — particularly along the jawline, chin, and neck. This is not hormonal acne in the colloquial sense. It is a measurable, mechanistic consequence of androgen excess. A 2025 systematic review and meta-analysis found that 43% of women with PMOS have acne, compared to 21% in the general female population.

Hirsutism — excess hair growth on the face, chest, or abdomen — affects a significant proportion of people with PMOS and is similarly a direct consequence of elevated free androgens, not a cosmetic coincidence. Androgenic alopecia — progressive hair thinning beginning at the part line or temples — follows the same mechanism in reverse: DHT (a potent form of testosterone) shortens the hair growth cycle and miniaturises follicles. Both conditions can often be improved by addressing the underlying hormonal environment, rather than treating the surface symptom alone.

The Three Faces of PMOS: One Condition, Many Presentations

One of the reasons PMOS went undiagnosed so often is that it presents differently in different people. The new PMOS framework formalises three dominant phenotypes, allowing clinicians to tailor investigation and treatment rather than applying a single protocol to a condition that can look completely different from one person to the next.

What Actually Changes Now That Medicine Got the Name Right

The name change is not immediate. The Lancet consensus paper outlines a three-year transition period before PMOS replaces PCOS in the International Classification of Diseases in 2028. In the meantime, both names will coexist — which means patients may still receive a 'PCOS' diagnosis from clinicians who haven't yet made the shift. What changes is the framing: a diagnosis of PMOS should trigger investigation of all three axes (endocrine, metabolic, reproductive) rather than routing the patient exclusively through gynaecology. For the 70% currently undiagnosed, that reframing could be the difference between a decade of fragmented care and an accurate diagnosis within the first appointment.

For anyone who has spent years being told their acne is a skincare issue, their weight is a willpower issue, or their irregular periods are stress — and has a quiet suspicion that something systemic was being missed — the science of PMOS is not an academic update. It is a clinical framework that finally describes the whole picture. The ovary was always a messenger. The message was always in the metabolism.